Victory Capital Management Inc. cut its position in Eli Lilly And Co (NYSE:LLY) by 16.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 78,590 shares of the company’s stock after selling 15,346 shares during the period. Victory Capital Management Inc.’s holdings in Eli Lilly And Co were worth $10,198,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in LLY. Oregon Public Employees Retirement Fund boosted its position in Eli Lilly And Co by 17,720.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 42,420,406 shares of the company’s stock valued at $367,000 after buying an additional 42,182,367 shares in the last quarter. Norges Bank acquired a new position in Eli Lilly And Co in the fourth quarter valued at about $1,056,086,000. FMR LLC boosted its position in Eli Lilly And Co by 83.9% in the fourth quarter. FMR LLC now owns 13,687,081 shares of the company’s stock valued at $1,583,870,000 after buying an additional 6,242,865 shares in the last quarter. Amundi Pioneer Asset Management Inc. boosted its position in Eli Lilly And Co by 165.4% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 6,012,822 shares of the company’s stock valued at $695,804,000 after buying an additional 3,747,482 shares in the last quarter. Finally, BlackRock Inc. boosted its position in Eli Lilly And Co by 3.0% in the fourth quarter. BlackRock Inc. now owns 68,956,519 shares of the company’s stock valued at $7,979,649,000 after buying an additional 2,030,845 shares in the last quarter. Hedge funds and other institutional investors own 80.69% of the company’s stock.

Shares of LLY traded up $0.53 on Friday, reaching $117.34. 37,194 shares of the company’s stock were exchanged, compared to its average volume of 12,465,346. The company has a debt-to-equity ratio of 5.50, a current ratio of 1.12 and a quick ratio of 0.85. The company has a market cap of $114.00 billion, a price-to-earnings ratio of 21.14, a price-to-earnings-growth ratio of 2.07 and a beta of 0.27. Eli Lilly And Co has a 12 month low of $81.65 and a 12 month high of $132.13.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $1.33 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.01. The business had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $5.12 billion. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. Eli Lilly And Co’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.31 earnings per share. As a group, analysts expect that Eli Lilly And Co will post 5.66 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Friday, May 17th will be paid a dividend of $0.645 per share. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.20%. The ex-dividend date is Thursday, May 16th. Eli Lilly And Co’s dividend payout ratio (DPR) is 46.49%.

A number of equities analysts have commented on the stock. Citigroup set a $124.00 price target on shares of Eli Lilly And Co and gave the company a “hold” rating in a research report on Tuesday, February 26th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Eli Lilly And Co in a research note on Monday, February 4th. Guggenheim downgraded shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 target price for the company. in a research note on Thursday, April 11th. Barclays reaffirmed a “buy” rating and issued a $140.00 target price on shares of Eli Lilly And Co in a research note on Sunday, April 14th. Finally, Credit Suisse Group set a $121.00 target price on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research note on Friday, March 22nd. Eleven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Eli Lilly And Co currently has an average rating of “Buy” and a consensus target price of $118.15.

In related news, SVP Stephen F. Fry sold 14,847 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $123.16, for a total transaction of $1,828,556.52. Following the completion of the sale, the senior vice president now directly owns 109,663 shares of the company’s stock, valued at $13,506,095.08. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 26th. The stock was sold at an average price of $131.41, for a total transaction of $26,939,050.00. Following the sale, the insider now directly owns 116,814,018 shares of the company’s stock, valued at $15,350,530,105.38. The disclosure for this sale can be found here. Over the last three months, insiders have sold 445,959 shares of company stock valued at $57,322,302. 0.11% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://theolympiareport.com/2019/05/24/eli-lilly-and-co-lly-holdings-reduced-by-victory-capital-management-inc.html.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Market Capitalization and Individual Investors

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.